Efficacy and safety of rituximab in primary IgA nephropathy: a retrospective study
Clinical and Experimental Nephrology · 2025-05 · 29 (5) · 616-623
DOI: 10.1007/s10157-024-02617-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Nephrology, online erschienen am 27.12.2024. Verfasst von Jingzhen Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Ningbo Yinzhou Second Hospital, No. 998, North Qianhe Road, Yinzhou District, Ningbo City, 315000, Zhejiang Province, China. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Rituximab, Immunologic Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The study aimed to evaluate the efficacy and safety of rituximab (RTX) in primary IgA nephropathy (IgAN).
Methods
A retrospective review was conducted on the medical records of 22 patients diagnosed with primary IgAN who received RTX treatment. The clinical data, including blood tests, urine examinations and estimated glomerular filtration rate (eGFR), were analyzed at four time point: baseline, 3 months, 6 months and 12 months. Adverse events were also recorded.
Results
Our study included 9 male and 13 female participants. The level of serum albumin significantly increased after three months with RTX applied ( P < 0.01). Furthermore, we observed a significant reduction in microalbuminuria and urine albumin-to-creatinine ratio at twelve months ( P < 0.01). However, there was no change in serum creatinine ( P = 0.08), urinary red blood cell ( P = 0.11) or eGFR ( P = 0.09) during the course of one year. Two cases achieved complete remission, while eleven cases experienced partial remission, resulting in an overall remission rate of 50.0%. During the treatment period, three patients developed infections and two patients encountered infusion-related adverse reactions.
Conclusion
In our retrospective study, RTX demonstrated a significant improvement in serum albumin levels and a reduction in proteinuria among primary IgAN patients. Although no statistically significant difference was observed in terms of renal function, there was an observable trend towards improvement. Therefore, we propose that RTX may be an alternative treatment option for primary IgAN patients who cannot tolerate glucocorticoids or immunosuppressants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Ningbo Yinzhou Second Hospital, No. 998, North Qianhe Road, Yinzhou District, Ningbo City, 315000, Zhejiang Province, China.
- Department of Nephrology, Ningbo Yinzhou Second Hospital, No. 998, North Qianhe Road, Yinzhou District, Ningbo City, 315000, Zhejiang Province, China. yinzhoujing@163.com.
Zitieren
APA
Li, J., Nie, Z., Li, G., & Bao, B. (2025). Efficacy and safety of rituximab in primary IgA nephropathy: a retrospective study. Clinical and Experimental Nephrology, 29(5), 616-623. https://doi.org/10.1007/s10157-024-02617-0
Vancouver
Li J, Nie Z, Li G, Bao B. Efficacy and safety of rituximab in primary IgA nephropathy: a retrospective study. Clinical and Experimental Nephrology. 2025;29(5):616-623. doi:10.1007/s10157-024-02617-0
BibTeX
@article{Li2025,
author = {Li, Jingzhen and Nie, Zhenyu and Li, Guofu and Bao, Beiyan},
title = {Efficacy and safety of rituximab in primary IgA nephropathy: a retrospective study},
journal = {Clinical and Experimental Nephrology},
year = {2025},
volume = {29},
number = {5},
pages = {616--623},
doi = {10.1007/s10157-024-02617-0}
}
EUVIMED